An ACE2-IgG4 Fc Fusion Protein Demonstrates Strong Binding to All Tested SARS-CoV-2 Variants and Reduced Lung Inflammation in Animal Models of SARS-CoV-2 and Influenza

BACKGROUND: The continued emergence of SARS-CoV-2 variants has caused concern that a constantly evolving virus will escape vaccines and antibody therapies. New approaches are needed. METHODS: We created and manufactured an ACE2 extracellular domain (ECD) fragment Fc fusion drug candidate, G921, and...

Descripción completa

Detalles Bibliográficos
Autores principales: Merigeon, Emmanuel Y., Yang, Dong, Ihms, Elizabeth A., Bassit, Leda C., Fitzpatrick, Elizabeth A., Jonsson, Colleen B., Schinazi, Raymond F., Block, David S., Olsen, Henrik S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Pathogens and Immunity 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9438944/
https://www.ncbi.nlm.nih.gov/pubmed/36072571
http://dx.doi.org/10.20411/pai.v7i1.491

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9438944/
https://www.ncbi.nlm.nih.gov/pubmed/36072571
http://dx.doi.org/10.20411/pai.v7i1.491

Ejemplares similares